Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin

Amrita Goyal, Maria Hordinsky, Aleksandr Lazaryan

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Brentuximab vedotin is a CD30-antibody/drug conjugate which has demonstrated excellent response in treating CD30-positive mycosis fungoides (MF) and anaplastic large cell lymphoma (ALCL). In this report, we present a patient with CD30-negative MF refractory to multiple other lines of therapy who demonstrated a dramatic response to brentuximab. This paradoxical response may be due to inadequate detection of CD30 expression by immunohistochemical techniques. From this case we see that even in the setting of apparent CD30 negativity, brentuximab may be a viable treatment option for patients who require bridging to stem cell transplant or seek successful palliation. This case highlights the point that rigid inclusion criteria for MF trials without use of more sensitive techniques to confirm lack of CD30 expression may inappropriate.

Original languageEnglish (US)
Article numbere12835
JournalDermatologic therapy
Issue number2
StatePublished - Mar 1 2019

Bibliographical note

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.


  • CD30
  • brentuximab
  • mycosis fungoides


Dive into the research topics of 'Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin'. Together they form a unique fingerprint.

Cite this